Hearing device company, Cochlear,
(ASX:COH) has invested €13 million in Nyxoah (SA)
Nyxoah is a medical device company focused on the development and commercialisation of a best-in-class hypoglossal therapy for the treatment of obstructive sleep Apnea.
Cochlear says it actively monitors the market for novel technologies that over the long term may leverage or enhance its core technology
The investment comes on the back of a new agreement with audio solutions company, GN last week.
Shares in Cochlear
(ASX:COH) are down 3.13 per cent to $169.96.
